Trial Profile
A Postmarketing Observational Study to Evaluate the Safety of ADASUVE (STACCATO Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Loxapine (Primary)
- Indications Agitation
- Focus Adverse reactions
- Sponsors Alexza Pharmaceuticals
- 06 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Mar 2022.
- 06 Oct 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Oct 2021.
- 03 May 2018 New trial record